
MajesTec5 RdMap👇 Could bispecifics—and now trispecifics—reshape frontline myeloma treatment? ✨ Back in May, I shared the #MagicTec roadmap. Now let’s zoom in on MajesTEC-5. One trial. Multiple cohorts. Several frontline questions: 🔹 What should induction look like? 🔹 How should we use these agents around ASCT? 🔹 What should maintenance contain? 🔹 Can selected strategies succeed without upfront ASCT? Clinical data are available from: • A/A1/B: teclistamab + Dara/Len ± bortezomib, followed by ASCT • E: talquetamab + Dara/Len, followed by ASCT • G: ramantamig + Dara/Len, followed by Ram–Dara without planned ASCT These are TRANSPLANT-ELIGIBLE patients—including arm G. MajesTEC-5 is exploring a redesign of the frontline treatment strategy. The transplant question is one part of that larger effort. Early responses are striking. Durability, toxicity, treatment burden and randomized comparisons will determine what changes practice. #MultipleMyeloma #ASH26 #Bispecifics #Trispecifics #HemeTwitter
It’s MajesTEC-1,2,3,4,5,7,9… but I call it #MagicTec ✨🧬 An easier way to remember the journey: 🔹 Magic 1 Advanced / heavily pretreated disease 🔹 Magic 3 1st+ relapse, non-Dara refractory (teclistamab + Dara moving earlier) 🔹 Magic 4 Maintenance after transplant 🔹 Magic 5 & 7 Frontline myeloma • transplant-eligible • transplant-ineligible 🔹 Magic 9 Dara-exposed / refractory early relapse strategy What is amazing is not just the speed… but the roadmap itself. The studies are progressively moving BCMA bispecific therapy: late line → early relapse → maintenance → frontline One scientific question at a time. One indication at a time. But accumulating very, very fast. ⚡ #MultipleMyeloma ##Bispecifics #HemeTwitter
































